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a b s t r a c t
Carbon nanotubes (CNTs) are a novel nanocarriers with interesting physical and chemical properties.
Here we investigate the ability of amino-functionalized multi-walled carbon nanotubes (MWNTs-NH3
þ)
to cross the Blood-Brain Barrier (BBB) in vitro using a co-culture BBB model comprising primary porcine
brain endothelial cells (PBEC) and primary rat astrocytes, and in vivo following a systemic administration
of radiolabelled f-MWNTs. Transmission Electron microscopy (TEM) conﬁrmed that MWNTs-NH3
þ
crossed the PBEC monolayer via energy-dependent transcytosis. MWNTs-NH3þ were observed within
endocytic vesicles and multi-vesicular bodies after 4 and 24 h. A complete crossing of the in vitro BBB
model was observed after 48 h, which was further conﬁrmed by the presence of MWNTs-NH3þwithin the
astrocytes. MWNT-NH3
þ that crossed the PBEC layer was quantitatively assessed using radioactive tracers.
A maximum transport of 13.0 ± 1.1% after 72 h was achieved using the co-culture model. f-MWNT
exhibited signiﬁcant brain uptake (1.1 ± 0.3% injected dose/g) at 5 min after intravenous injection in
mice, after whole body perfusion with heparinized saline. Capillary depletion conﬁrmed presence of f-
MWNT in both brain capillaries and parenchyma fractions. These results could pave the way for use of
CNTs as nanocarriers for delivery of drugs and biologics to the brain, after systemic administration.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Carbon nanotubes (CNT) are novel nanomaterial with attractive
physical, chemical and electronic properties [1]. One of the most
interesting characteristics of functionalized CNTs (f-CNTs), from a
drug delivery point of view, is their ability to translocate across
plasma membranes and enter the cells either passively by direct
translocation across membranes or actively via endocytosis [2].
Nano-meshworks of single-walled carbon nanotubes (SWNTs) and
MWNTs on glass slides have been shown to support neuronal
growth and responsiveness of rat hippocampal neurones. CNTs
improved the excitability of the neurones by interfacing with the
cells creating circuit shortcuts [3]. CNTs have also shown intrinsic
therapeutic action in stroke prevention in vivo without carrying a
therapeutic cargo. Lee et al. have studied the intrinsic therapeutic
effect of amino-functionalized SWNTs in stroke prevention. A ce-
rebral ischemia injury rat model was used in this study, with
SWNTs injected into the lateral ventricle of the brain. The extent of
neuronal damage following the ischemic injury was signiﬁcantly
lower in the SWNT-treated group compared to the control. The
therapeutic effect persisted for 7 days after treatment showing the
potential of SWNTs in stroke prevention [4]. Moreover, we have
previously demonstrated the successful delivery of caspase-3 siRNA
by CNTs to the brain in vivo. MWNTs-NH3þ were complexed with
caspase-3 siRNA to provide a delivery platform superior to the
intracerebral administration of siRNA alone. The peri-lesional ste-
reotactic administration of MWNTs-NH3þ:caspase-3 siRNA com-
plexes resulted in reduced neuronal damage and enhanced motor
function recovery in an Endothelin-1 rat stroke model [5]. In
another study, the delivery of CpG oligonucleotide to brain glioma
was enhanced using SWNTs. SWNTs-CpG conjugates were injected
into the brain using a single intracranial injection and the uptake
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was evaluated using ﬂow cytometry and confocal microscopy. The
data suggested that conjugating CpG to SWNTs signiﬁcantly
enhanced the delivery into tumour-associated inﬂammatory cells
compared to the free CpG [6]. These studies highlight the impor-
tance of using CNTs with/without therapeutic cargo to reach targets
in the brain and eradicate tumours. However, none of the
mentioned studies used systemic administration where crossing
the BBB may constitute a major obstacle to CNTs brain delivery.
CNTs have shown the ability to permeate through biological
membranes with evidence of membrane sealing due to their
unique needle-like structure [7]. However, no studies on their
ability to cross the BBB in vitro or in vivo have been reported.
Therefore, in this workwe hypothesize that MWNTs-NH3þ, used as a
prototype, are able to cross the PBEC cells in vitro, and accumulate
in the brain following intravenous injection. The mechanism of BBB
crossing was studied in vitro, using a co-culture model of porcine
brain endothelial cells (PBEC) and primary rat astrocytes. MWNTs-
NH3þwere shown to be able to cross the PBEC layer as conﬁrmed by
transmission electron microscopy (TEM) and gamma counting. f-
MWNT were also found in the astrocyte layer of the co-culture.
Brain uptake and access to mouse brain parenchyma, after sys-
temic injection, were conﬁrmed by gamma counting and capillary
depletion, respectively.
2. Materials and methods
2.1. Materials
Newborn Calf heat-inactivated Serum and Bovine Plasma-Derived Serum were
obtained from First-Link, UK Ltd. Iscove's Modiﬁed Dulbecco's Medium (IMDM),
High glucose Dulbecco's Modiﬁed Eagle's Medium (DMEM), Low glucose DMEM,
Medium 199, Phosphate Buffered Saline (PBS), 10, pH 7.4, Minimum Essential
Medium/HEPES, Penicillin-Streptomycin 100X, 0.05% Trypsin-EDTA (1X) with
Phenol Red, GlutaMAX™ Supplement were obtained from Invitrogen, Life Sciences,
UK. Collagenase type 3, Trypsin powder, Deoxyribonuclease I were obtained from
Worthington Biochemicals Inc, USA. Nylon mesh 60 mm and 150 mm pore size,
50 mm disks were purchased from PLASTOK, UK. Sodium chloride, Trypsin solution
from porcine pancreas, Cytosine arabinoside, Poly-L-lysine, Hanks' Balanced Salt
solution (HBSS), Paraformaldehyde, HEPES, N,N-Dimethylformamide, 8-(4-
Chlorophenylthio)adenosine 30 ,50-cyclic monophosphate sodium salt, 4-(3-Butoxy-
4-methoxybenzyl)imidazolidin-2-one, Hydrocortisone, Dounce tissue grinder set,
Fibronectin from bovine plasma, Propylene oxide, Uranyl acetate dihydrate, N,N-
Diisopropylethylamine, Diethyl enetriamine pentaacetic acid, Ninhydrin, Dimethyl
sulfoxide, Heparin sodium salt from porcine intestinal mucosa, Puromycin dihy-
drochloride from Streptomyces alboniger, Triton™ X-100, Osmium tetroxide, Costar
Transwell™ permeable supports 3.0 mm pore polyester and polycarbonate mem-
brane were all obtained from SigmaeAldrich, UK. Fluoropore PTFE hydrophobic
0.22 mm membrane and Glutaraldehyde, 25% Aqueous Solution were purchased
from Merck Millipore, UK. Precision Bottle-top ﬁlter unit MF75 Series disposable
SFCA membrane and 70 mm cell Strainer were obtained from BD Falcon™, UK.
Dodecenyl Succinic Anhydride, Araldite CY212, Tris(dimethylaminomethyl)phenol,
F2 Finder Grids Copper 3.05 mm were obtained from AgarScientiﬁc, UK. Ultra Dia-
mond Knife 45 was obtained from DiATOME, UK. MiniSart hydrophilic syringe
ﬁlters (0.2 mm) were purchased from Sartorius Stedim UK Ltd. Pristine multi-walled
carbon nanotubes, used for preparation of MWNTs-NH3þ (diameter ¼ 20e30 nm,
Length ¼ 0.5 mm), Batch # 1237YJS were purchased from Nanostructured and
Amorphous materials Inc. CytoTox 96® Non-Radioactive Cytotoxicity Assay was
obtained from Promega Corporation, UK. Sodium cacodylate trihydrate and Opti-
phase Trisafe scintillation cocktail were purchased from ThermoFisher Scientiﬁc.
Sucrose [U-14C speciﬁc activity > 350 mCi/mmol ] 1.85 MBq was obtained from MP
Biomedicals. The radioactive tracer [111In]Cl3 was obtained from Amersham Phar-
macia Biosciences as an aqueous solution and used without further puriﬁcation.
2.2. Functionalization of MWNTs derivatives
MWNTs constructs (MWNTs-NH3þ, DTPA-MWNTs) were synthesized following
previously published methods [5,8]. Detailed description of the synthesis method-
ology can be found in the SI Text. The synthesis of Boc-protected amino acid is
described in Refs. [8,9]. The synthesized MWNTs were characterized by Kaiser test
and thermogravimetric analysis. All details are provided in SI Text.
2.3. Radio-labelling of DTPA-MWNTs with 111Indium
DTPA derivatives of f-MWNT (1 mg/ml in water) were diluted with an equal
volume of ammonium acetate buffer (0.2 M, pH 5.5) yielding a ﬁnal acetate buffer of
0.1 M, pH 5.5, towhich 111InCl3 was added. The reactionwas carried out for 30min at
room temperature, and it was then terminated by the addition of EDTA quenching
solution (0.1 M, 1:20 of total volume) to chelate the unreacted indium. The labelling
efﬁciency of [111In]DTPA-MWNTs was determined by thin layer chromatography
(TLC). Brieﬂy, a small volume of [111In]DTPA-MWNTs was diluted 5 times in PBS, and
1 ml was applied on silica gel impregnated glass ﬁbre sheets (Varian, USA). The TLC
was carried out in 0.1 M ammonium acetate mobile phase containing 50 mM EDTA,
and allowed to dry before counting the signal using the Cyclone phosphor detector
(Packard Biosciences, UK). The spot at the application point of the TLC strip indicated
the presence of [111In]DTPA-MWNTs whereas the signals at the solvent front were
indicative of the [111In]EDTA and/or [111In]DTPA. The [111In]DTPA-MWNTs disper-
sions were also checked for [111In]DTPA contamination, as residual trace from DTPA
chemical reaction, by TLC using 3.5% NH4þ:methanol (1:1) as the mobile phase. In
this case, the signals acquired at the application point were the result of the
immobile [111In]DTPA-MWNTs or the colloidal indium (forms in basic conditions)
whereas the signals at the solvent front indicated the presence of [111In]DTPA in the
mixture. The stability of the [111In]DTPA-MWNTs formulation was tested by mixing
with equal volume of PBS or serum and incubated at 37 C for 24 h after radio-
labelling. Any unbound indium was removed by a centrifugation step prior to in-
cubation with cells. TLC with 0.1 M ammonium acetate mobile phase containing
50 mM EDTA was used to conﬁrm the stability of the constructs during the time
course of the experiment by taking samples from the apical and basal chambers.
[111In]EDTA was used as a control.
2.4. The modiﬁed lactate dehydrogenase (LDH) assay
PBEC were seeded into a 24 well plate (2  104 cells per cm2) and allowed to
reach conﬂuence. The culture medium was changed to serum-free medium 24 h
before adding the MWNTs-NH3þ to the cells. The MWNTs-NH3þ dispersions were
prepared in 5% dextrose solution, and then added onto the cells at 20 mg/ml and
50 mg/ml ﬁnal concentrations. After 24 and 72 h, light microscopy images were
captured. The cells were thenwashed twicewith HBSS, and then lysedwith Triton X-
100 (0.09% v/v in fresh DMEM media). The cell lysates were collected and centri-
fuged for 15 min at 20,800 g (Eppendorf 5810R, Germany). The LDH content was
assayed following the CytoTox 96® assay protocol (Promega Corporation, USA), and
the signal was measured at 490 nm using a FLUOstar Omega microplate reader
(BMG Labtech, Germany).
2.5. Isolation of primary porcine brain endothelial cells (PBEC)
The PBEC isolation method was based on that originally developed for bovine
brain endothelium by Rubin et al. [10] and was further modiﬁed and improved by
Abbott and co-workers [11]. The porcine brains were delivered from the abattoir in
ice-cold IMDM medium (IMDM supplemented with 100 U/100 mg/ml penicillin/
streptomycin) and were kept on ice throughout the isolation. Brain hemispheres
were washed brieﬂy with ice-cold phosphate-buffered saline and cerebrums were
removed. The meninges were peeled off with forceps from the surface of the brain
and from inside the grooves, then the white matter was pinched off from inside the
hemispheres. The cortices were collected in a sterile beaker containing MEM/HEPES
medium (25 mM HEPES and 10% v/v FBS and 100 U/100 mg/ml penicillin/strepto-
mycin) and chopped up with a sterile scalpel. For initial homogenization, the
chopped hemispheres were forced through a 50 ml syringe into a T75 culture ﬂask
containing ice cold MEM/HEPES then further homogenized in a 40 ml Wheaton
Dounce tissue grinder. The resulting homogenate was collected in a T-175 ﬂask and
ﬁltered initially through a 150 mm nylon mesh then the ﬁltrate was re-ﬁltered
through a 60 mm nylon mesh. The brain capillaries are trapped on the nylon
meshes, which were then placed in a Petri dish containing the digest mix (colla-
genase type 3 (223 U/mg), trypsin (211 U/mg), DNase (2108 U/mg), FBS (10% v/v) and
penicillin/streptomycin (100 U/100 mg/ml) dissolved in M199 medium) and incu-
bated at 37 C for 1 h. The brain capillaries were collected from the nylon meshes
(capillaries collected on the 60 and 150 mm nylon meshes were kept separate) by
trituration with digest mix and then centrifuged at 240 g (Eppendorf® 5810R
centrifuge, Germany) for 10min. The supernatant was aspirated and the pellets were
resuspended in 10 ml MEM/HEPES. This step was repeated twice and ﬁnally the
pellets were resuspended in freshly-prepared freezing medium (FBS containing 10%
v/v dimethyl sulfoxide). The suspension was then aliquoted in cryo-vials and stored
at 80 C overnight in a freezing container (1 C per min freezing rate), and then in
liquid nitrogen for long-term storage. PBEC 60's and 150's refer to brain capillaries
collected on 60 and 150 mm meshes, respectively.
2.6. Culturing and maintenance of PBEC
To aid PBEC adhesion to cell culture vessels, the T-75 culture ﬂasks were coated
with 4 ml rat-tail collagen (330 mg/ml) in sterile de-ionized water for two hours at
RT. Following the collagen coating, the ﬂasks were washed twice with HBSS, 4 ml of
ﬁbronectin (7.5 mg/ml) was then added to each ﬂask for 2 h at RT. After the cross-
linking of collagen to ﬁbronectin, the ﬂasks were washed with HBSS. PBEC culture
medium was freshly prepared to ensure that all the supplements were available to
aid cell growth and differentiation. The optimum growthmedium used for PBECwas
low glucose DMEM supplemented with 10% v/v plasma-derived bovine serum,
100 U/100 mg/ml penicillin/streptomycin, 2 mM Glutamax™, 125 mg/ml heparin and
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4 mg/ml puromycin. The medium was sterile-ﬁltered using a 0.2 mm syringe ﬁlter. A
vial of PBEC 60's was taken out of liquid nitrogen and allowed to thaw over 60 s in a
37 C water bath. The vial was then taken into a sterile hood and diluted in 20 ml of
warm PBEC medium. The suspension was then plated into the coated T-75 ﬂasks.
The medium was changed every 3 days until the culture was 50% conﬂuent.
2.7. Isolation of primary rat astrocytes from post-natal rat pups
Primary astrocytes type I were isolated from 0 to 2 day old Wistar rat pups
following the method of Abbott et al. [12]. Brieﬂy, the brains were removed from the
skulls aseptically in the hood and were kept in ice-cold dissection buffer (Ca2þ and
Mg2þ free HBSS, 10 mM HEPES buffer, 100 U/ml penicillin G and 100 mg/ml strep-
tomycin). The brains were dissected to remove the cerebrum, midbrain structures,
choroid plexus and the hippocampus. Themeninges were carefully removed and the
cortices were placed in ice cold dissection buffer. The cortices were chopped ﬁnely
with a sterile surgical scalpel, then an equal volume of trypsin solution (1.25 mg/ml)
was added and the mixture was incubated at 37 C for 30 min. Following the in-
cubation period, the trypsin was neutralized by adding an equal volume of serum-
containing nutrient medium (high glucose DMEM, 10% v/v fetal bovine serum, 1%
Glutamax™, 100 U/ml penicillin G and 100 mg/ml streptomycin), and centrifuged for
5 min at 306 g (Beckman Coulter Allegra x-22R). The pellet was resuspended and
triturated in 2 ml culture medium. The resulting homogenate was ﬁltered through a
70 mm sieve and cells were counted on a haemocytometer. Cells were then seeded
(25,000 cells/cm2) in poly-L-lysine (10 mg/ml) coated T25 ﬂasks. The cultures were
incubated at 37 C in a humidiﬁed chamber with 5% CO2 and the culture medium
was changed 24 h after seeding, and then every other day. At sub-conﬂuence (7e9
days after seeding) the contaminating cells were eliminated by shaking the ﬂasks on
an orbital shaker for 24 h. Further puriﬁcation was carried out at conﬂuence by
adding cytosine arabinoside (10 mM) to the ﬂasks in the morning and replacing the
culture medium in the evening for 5 days.
2.8. Setting up the BBB co-culture Transwell™ system
One week before the experiment, astrocytes were sub-cultured into a 12-well
plate coated with 10 mg/ml poly-L-lysine. The medium was changed one day
before introducing the Transwell™ ﬁlters in the well plate. A vial of PBEC 60's was
thawed into two T-75 ﬂasks, and the growth rate was monitored after three days.
When the cells reached 50% conﬂuency, they were sub-cultured onto 3.0 mm pore
polyester inserts and placed in the wells above the astrocytes. The cells were
incubated at 37 C in a humidiﬁed chamber with 5% CO2 until PBEC formed a
monolayer of endothelial cells on the ﬁlter. To stimulate the formation of tight
junctions between adjacent endothelial cells, the culture medium was changed to
serum-free medium for 24 h before starting uptake studies (third day of co-culture)
as described previously [11]. In addition, the apical and basal chambers were sup-
plemented with pCPT-cAMP (250 mM), RO-20-1724 (17.5 mM) and hydrocortisone
(550 nM). After 24 h, the trans-endothelial electrical resistance (TEER) was
measured (EVOM epithelial voltohmmeter with STX2 electrode, World Precision
Instruments, UK) to assess the tightness of the BBBmodel. Permeability experiments
were performed when TEER values were >200 U cm2.
2.9. Transport of f-MWNT across the BBB by electron microscopy
A PBEC/astrocyte co-culture BBB model was set up as detailed above. f-MWNTs
were added to the apical chamber of the inserts (20 mg/ml) to examine interaction
between f-MWNT and the PBEC monolayer by ultra-structural imaging. The cellular
uptake experiments were carried out for 4, 24 and 48 h at 37 C. To study the energy-
dependency of f-MWNT uptake into PBEC, the PBEC/astrocytes BBB model was pre-
incubated at 4 C for 30 min followed by the addition of f-MWNT (20 mg/ml) to the
apical chamber, as above. The plate was then incubated at 4 C for a further 4 h. All
uptake experiments were terminated by ﬁxing the PBEC monolayer and the astro-
cytes with 2.5% glutaraldehyde solution in 0.1 M cacodylate buffer for 1 h at RT.
2.10. Sample processing of the Transwell™ ﬁlters and astrocytes for electron
microscopy imaging
Transwell™ ﬁlters containing PBEC and the astrocytes layer were ﬁxed using 1%
osmium oxide for the purpose of TEM/scanning TEM (STEM) examination. The ﬁlters
were rinsed with 0.1 M cacodylate buffer, and de-hydrated in a series of dehydration
steps using increasing concentrations of ethanol (70%, 90% and absolute ethanol)
being incubated for 10 min at each concentration. Propylene oxide was added to the
ﬁlters for 15 min, followed by the addition of a 1:1 mixture of propylene oxide:
epoxy resin for 1 h. The ﬁlters were then embedded into epoxy resin blocks (Araldite
CY212, DDSA and DMP30) and left in 60 C oven for 3 days to polymerize. Ultrathin
sections were cut using a diamond knife on a microtome (Leica Reichert Ultracut)
and collected on copper 200-mesh grids. The grids were stained with uranyl acetate
for examination by TEM (Philips CM12, FEI Tecnai G2 F20, USA)/and low voltage
STEM (FEI Magellan 400L XRSEM, USA).
2.11. Electron microscopy imaging of processed Transwell™ ﬁlters
Bright ﬁeld TEM images of the PBEC and astrocytes samples were acquired using
a Philips CM12 operating at 80 kV; this accelerating voltage did not affect the
structure of the f-MWNT in the examined samples. The objective aperture was used
to image the samples. Low voltage STEM imaging was carried out on the FEI extreme
high resolution Magellan 400L SEM running at 10e15 kV ﬁtted with a second
generation FEI retractable STEM detector. This detector has multiple segments that
allow capture of different signals simultaneously. The central part of the detector
collects electrons at a normal angle producing conventional bright ﬁeld images.
Scattered electrons collectedwith an annular segment around the central part of the
detector produce annular dark ﬁeld (ADF) images. ADF images feature an inverse
contrast that allows resolution of high electron dense structures, such as carbon
nanotubes and metal catalysts with more detail. High angle annular dark ﬁeld
(HAADF) images are produced from scattered electrons that are collected on an
annular dark ﬁeld detector at higher angles; the intensity in HAADF images is
directly related to the atomic number of the elements within the sample [13].
Finally, high-resolution TEM (HRTEM) images and STEM images (reported in SI)
were obtained using a FEI Tecnai G2 F20 TEM running at 120 kV.
2.12. Transport studies of [111In]DTPA-MWNTs and [14C]sucrose across PBEC
The PBEC/astrocyte co-culture model was set up in a 12-well plate. [111In]DTPA-
MWNTs (20 mg/ml) was added to the apical chamber of the Transwell™ inserts, and
the plate was incubated at 37 C up to 72 h. To examine the effect of temperature on
the transport, three inserts were initially incubated at 4 C for 4 h, followed by re-
incubation at 37 C. To assess the potential damage of [111In]DTPA-MWNTs on the
tight junction assembly, the permeability marker [14C]sucrose (2.4  105 dpm) was
added to the apical chamber of transwells™ (in the presence or absence of MWNTs).
The free isotope [111In]EDTAwas used as another control. To assess the permeability
of [111In]DTPA-MWNTs across the membrane ﬁlter (3.0 mm pore size), experiments
were run in parallel where the ﬁlters were treated with the above conditions in the
absence of PBEC/astrocytes. At speciﬁed time points (1 min, 3 min, 5 min, 10 min,
15 min, 30 min, 45 min, 60 min, 120 min, 240 min, 1080 min, 2880 min and
4320 min), 0.5 ml aliquots were taken from the basal chamber and stored in counter
vials. The medium in the basal chamber was replenished with warm medium to
maintain sink conditions. 111In signal was quantiﬁed as counts per minute (CPM)
using the 1282 CompuGamma CS Gamma Counter (LKB Wallac, USA). When111In
decayed, 14C signal was quantiﬁed using liquid scintillation method (LS 6500 scin-
tillation counter, Beckman Coulter, USA), after the addition of 4 ml of the OptiPhase
liquid scintillation cocktail (ThermoFisher, UK) to each tube. Percentage uptake was
calculated from the total dose added to each well. Results were expressed as
mean ± SD (n ¼ 3).
The apparent permeability coefﬁcient (Papp) was calculated using the following
equation [14];
Papp ¼ DCR
Dt
VR
A* C0
DCR/Dt is the change in concentration in the receiving chamber over time. This
value was taken as the slope of the linear correlation (concentrations vs time) from
short time point intervals (3 mine60 min). C0 is the starting concentration in the
donor chamber (CPM), VR is the volume of the donor chamber (ml) and A is the
surface area of the Transwell™ ﬁlter (cm2).
2.13. Tissue bio-distribution of [111In]DTPA-MWNTs in mice by g-scintigraphy
All in vivo experiments were conducted under the authority of project and
personal licences granted by the UK Home Ofﬁce and the UKCCCR Guidelines (1998).
Tissue biodistribution of [111In]DTPA-MWNTs was measured by g-scintigraphy. Fe-
male C57/Bl6 mice aged 5e6 weeks were anaesthetized by isoﬂurane inhalation and
intravenously (i.v.) injected with [111In]DTPA-MWNTs (50 mg, 0.5 MBq) in 100 ml PBS
via a single tail vein injection. At 5 min, 30 min, 1 h, 4 h and 24 h after injection, a
whole body perfusion was performed on animals using 25 ml of heparinized saline
(1000 U/L) through the left ventricle of the heart in order to wash out residual or
loosely bound [111In]DTPA-MWNTs from the blood vessels. All the major organs
including skin, liver, spleen, kidneys, heart, lungs, muscle, bone, brain, stomach and
intestine were then harvested post-mortem. Excised organs were weighed and the
radioactivity was measured by g-scintigraphy (LKB Wallac 1282 Compugamma,
PerkinElmer). The results are expressed as % injected dose per organ (%ID,
mean ± SD, n ¼ 3) or % injected dose per gram tissue (%ID/g, mean ± SD, n ¼ 3) and
statistically analyzed using 1-way ANOVA.
2.14. Brain capillary depletion
Brain tissues were subjected to a further capillary depletion method to separate
the parenchyma from brain capillaries. Brain tissue was placed in a glass homoge-
nizer in 0.8 ml of ice cold depletion buffer (10 mMHEPES in HBSS, pH 7.4). The brain
was homogenized with 15 stokes of the pestle, and 1.6 ml of depletion buffer con-
taining 26% dextran (148 kDa) was added into the homogenizer. The brain was
further homogenized with 3 strokes of the pestle. Brain homogenate was centri-
fuged at 3220 g for 15 min. Brain parenchyma (supernatant) and brain vasculature
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(pellet) were collected into scintillation vials and the activity was measured using
gamma counting. The results are expressed as % injected dose per organ (%ID,
mean ± SD, n ¼ 3) and statistically analyzed using 1-way ANOVA.
3. Results
3.1. Chemical functionalization of MWNTs-NH3
þ
Pristine MWNTs were functionalized with 1, 3-dipolar cyclo-
addition (Scheme S1). The cycloaddition reaction on MWNTs was
performed using a Boc-protected amino acid and formaldehyde.
Following this reaction, the Boc-groupwas deprotected using acidic
conditions. The introduction of functional groups to the sidewalls of
the pristine material was conﬁrmed by TGA and Kaiser test. Kaiser
test is a quantitative test based on the reaction of the ninhydrin
reagent with the free amine group [15]. Due to the potential ag-
gregation of MWNTs-NH3þ, not all amine groups may have reacted
with the ninhydrin reagent rendering this test semi-quantitative in
this instance. TGA on the other hand offers quantitative amine
loading values by assessing the weight loss exhibited upon heating
the sample to 1000 C. TGA results are therefore considered more
accurate to quantify amine loading. Fig. S1 shows the TGA results of
the synthesized MWNTs. The pristine MWNTs exhibited high
thermal stability up to 750 C after which they started to decom-
pose. In comparison, MWNT-NH3þ exhibited 9% mass loss at 600 C,
which corresponds to 529 mmol of amine groups per gram of
MWNTs. Additionally, MWNT-NH3þ started to decompose at a
temperature lower than the decomposition temperature (750 C) of
the pristine material, which also indicated the conjugation of
functional groups to the MWNTs. This data was further conﬁrmed
using Kaiser test to assess the amount of amine loading on the
MWNTs. Fig. S2A shows the UVevis spectrum of the MWNT-NH3þ
after the Ninhydrin reaction. The spectrum showed an absorbance
peak at l ¼ 575 nm indicating the presence of amine groups on the
sidewalls of MWNTs.
DTPA-MWNTs were synthesized from MWNT-NH3þ as detailed
in the SI Text. The ammonium groups of the MWNT-NH3þ were
neutralized using Et3N to initiate the reaction with DTPA. The
conjugation of DTPA to the amine groups was conﬁrmed by the
negative Kaiser test (Fig. S2A). DTPA-MWNTs (Fig. S1) showed 26%
mass loss at 600 C by TGA corresponding to 493 mmol of DTPA
groups per gram of MWNTs. The above results indicated the suc-
cessful conjugation of DTPA to MWNT-NH3þ.
Fig. 1A shows the improvement in MWNTs-NH3þ and DTPA-
MWNTs aqueous dispersibility compared to that of the pristine
material. TEM images conﬁrmed that both constructs appeared
well dispersed in water (Fig. 1B). The length and diameter distri-
bution of MWNT-NH3þ is shown in Fig. S2B. The median of the
length and diameter was 500 nm and 18.9 nm, respectively.
3.2. Assessing the toxicity of MWNTs-NH3
þ on PBEC
The modiﬁed LDH assay was used to assess the potential cyto-
toxicity of MWNTs-NH3þ on PBEC relying on the percentage of LDH
enzyme remaining within the cell reﬂecting viability of the cells
[16] as we previously reported [17]. Dimethyl sulfoxide (DMSO)
(10% v/v) was used as a positive control in this experiment. Two
concentrations of MWNTs-NH3þ were tested: 20 mg/ml and 50 mg/
ml. The culture medium was changed to serum-free medium 24 h
before starting the experiment to mimic the conditions of the
transport experiment.
The modiﬁed LDH assay (Fig. 1C) showed that MWNTs-NH3þ
caused no statistically signiﬁcant toxicity (p > 0.05) on the endo-
thelial cells at the tested concentrations after 24 and 72 h. However,
the viability of the cells treated with 10% DMSO, used as a positive
control, was signiﬁcantly lower than that of the control at 24 h
(p < 0.01) and 72 h (p < 0.001). This reduction in viability conﬁrmed
the validity of the LDH assay to assess the viability of PBEC after
incubation with MWNTs-NH3þ. The lack of toxicity proved that
MWNTs-NH3þ are safe to use in primary endothelial cell uptake
studies under the conditions described. Despite the absence of toxic
effects of MWNTs-NH3þ on the viability of PBEC, the lowest con-
centration (20 mg/ml) was used in all transport uptake experiments.
3.3. The interaction of MWNTs-NH3
þ and PBEC monolayer by low
voltage scanning transmission electron microscopy (STEM)
The ﬁrst evidence of the interaction between f-MWNTs and
PBECwas obtained from light microscopy imaging. Bright ﬁeld light
microscopy images conﬁrmed the interaction between the
MWNTs-NH3þ and the endothelial cells after 24 and 72 h incubation
(Fig. S3A, B). The interaction between MWNTs-NH3þ and PBEC was
evident after 24 h, where MWNTs-NH3þ appeared associated with
the endothelial cells. After 72 h, the interaction between MWNTs-
NH3þ and PBECwasmore prominent. Even though theMWNTs-NH3þ
appeared to accumulate within the cell after 24 and 72 h in a
concentration-dependent manner, light microscopy was not sufﬁ-
cient to conﬁrm the extent of uptake at the tested time points.
To investigate the ability of f-MWNTs to cross the PBEC mono-
layer, we used a co-culture BBB model of primary porcine endo-
thelial cells and primary astrocytes. The BBBmodel was established
in a Transwell™ system. The primary astrocytes were grown at the
bottom of the culture plate and Transwell™ ﬁlters were then
inserted into the well plates. Co-culturing endothelial cells with
astrocytes has previously been shown to improve the polarized BBB
phenotype of brain endothelial cells in culture, especially impor-
tant for complex processes such as transcytosis [18,19]. PBEC was
allowed to form a monolayer on a porous polyester ﬁlter creating
the main BBB interface that is supported by mediators released
from the primary astrocytes. Depriving the cells of serum enhanced
the formation of tight junctions and allowed the polarization of
endothelial cells in response to the growth factors for the primary
astrocytes [11,20]. TEER measurements were carried out to monitor
the tightness of the PBECmonolayer. TEER was measured after 24 h
of serum deprivation (241.79 ± 27.76 U cm2, n ¼ 8).
TEM images (Fig. 2Ai) show the interaction of MWNTs-NH3þ and
the plasma membrane of the endothelial cells after 4 h of incuba-
tion. MWNTs-NH3þ were able to interact with the plasma mem-
brane of PBEC and triggered the formation of lipid rufﬂes that
initiated the endocytosis sequence to engulf the MWNTs-NH3þ, as a
ﬁrst step in transcytosis. After 24 h of incubation, most of the
MWNTs-NH3þwere observedwithin endoplasmic vesicles (EVs) and
multi-vesicular bodies (MVBs) (Fig. 2Aii, Figs. S4 and S5A). This
vesicular uptake allowed the clusters of MWNTs-NH3þ into the PBEC
monolayer as a second step in the transcytosis sequence after
interaction with the plasma membrane occurred. The TEM images
captured at 24 and 48 h conﬁrmed the third step of the transcytosis
process (Fig. 2Aiii and Fig. S4). Some MWNTs-NH3þ were found on
the basal side of PBEC or within partly open vesicles facing the basal
chamber at 24 h (Fig. S5). This provided the ﬁrst evidence of the
complete crossing of the endothelial cell via transcytosis. The data
obtained here show for the ﬁrst time that chemically functionalized
MWNTs-NH3þ are able to cross the BBB in vitro.
To gain a better understanding of the behaviour of MWNTs-NH3þ
within the endothelial cells, low voltage STEM imaging was
employed as an advanced imaging method allowing the capture of
high-resolution images of the MWNTs-NH3þ within PBEC. For this
purpose, an extremely high resolution SEM ﬁtted with a STEM
detector was used. STEM images, especially ADF and HAADF, pro-
vided extra information regarding the transcytosis of MWNTs-NH3þ.
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All the imaged sections were stained with osmium tetroxide and
uranyl acetate, resulting in high contrast images of cellular lipid
membrane and sub-cellular structures due to the high atomic
number of osmium [21]. Therefore, ADF and HAADF images re-
ﬂected the state and integrity of the plasma membrane and ve-
sicular membranes during the transcytosis stages of MWNTs-NH3þ.
They also showed the behaviour of the highly electron dense
MWNTs-NH3þwithin PBEC. The MWNTs-NH3þwere observed in EVs
after 4 and 24 h (Fig. 2Bi and Bii). After 48 h, MWNTs-NH3þ clusters
were observed in partly open vesicles fused with the abluminal
plasma membrane with some MWNTs-NH3þ exiting the PBEC
(Fig. 2Biii) matching the data of the conventional TEM. The vesicles
after 48 h appeared larger (1049 ± 222.3 nm, n¼ 5 cells) than those
after 24 h (712 ± 106.1 nm, n ¼ 5 cells), which may indicate that
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Fig. 1. The dispersibility of f-MWNTs constructs and the toxicity of MWNTs-NH3þ on PBEC after 24 and 72 h of uptake. The water dispersibility of the functionalized MWNTs-
NH3þ and DTPA-MWNTs in water as observed visually (A) and by TEM examination (B). (C) The modiﬁed LDH assay was carried out to evaluate cell viability after 24 and 72 h of
incubation at 20 and 50 mg/ml. 10% DMSO (v/v) was used as positive control. MWNTs-NH3þ had minimal effect on cell viability after 24 and 72 h while the viability of the cells treated
with 10% DMSO was signiﬁcantly reduced compared to the control at both time points. MWNTs-NH3þ did not affect the viability of PBEC up to 50 mg/ml (one-way ANOVA test;
*p < 0.05, **p < 0.01, ***p < 0.001, n ¼ 3).
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multiple vesicles fused together to form this large structure. The
MWNTs-NH3þ were not observed within the tight junctions during
the uptake process, which suggested that MWNTs-NH3þwere solely
dependent on the transcellular route to cross the BBB, and they
were not able to cross paracellularly.
The intact tight junctions suggested that the transcytosis of
MWNTs-NH3þ has no impact on BBB integrity. This is very impor-
tant from a toxicological and drug delivery point of view as it
shows the ability of MWNTs-NH3þ to cross the BBB in vitrowithout
affecting the permeability and healthy function of the BBB.
MWNTs-NH3þ were mainly observed in EVs and MVBs, but were
not spotted within other sub-cellular structures. Themitochondria
appeared free of any interaction with MWNTs-NH3þ, which is
vitally important for the healthy function of the endothelial cell.
The interaction of MWNTs-NH3þ with speciﬁc sub-cellular targets
i.e. EVs or MVBs indicates that the MWNTs-NH3þ were following a
speciﬁc trafﬁcking pathway within the endothelial cells. This
observation is important as the MWNTs-NH3þ used in this study
were not functionalized with surface ligands for speciﬁc receptors,
yet the uptake appears to take place in an organized and speciﬁc
manner. ADF and HAADF images (Fig. S5Aiii and Bii) showed that
upon release of MWNTs-NH3þ from PBEC, the vesicular membrane
was intact and complete at the edges of the releasing vesicle. This
observation further conﬁrmed that the release of MWNTs-NH3þ is
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Fig. 2. The transcytosis pattern of MWNTs-NH3þ across the PBEC monolayer following the incubation of MWNTs-NH3þ with an in vitro BBB model. MWNTs-NH3þ (20 mg/ml)
were added to the apical chamber and incubated with the PBEC for (i) 4, (ii) 24 and (iii) 48 h. (A) Bright ﬁeld TEM images of polyester ﬁlters showing the initial interaction of
MWNTs-NH3þ with the PBEC monolayer after 4 h (i). After 24 h (ii), the MWNTs-NH3þ clusters appeared within endocytic vesicles or multi-vesicular bodies. The MWNTs-NH3þ-
containing vesicles showed evidence of fusion with the abluminal plasma membrane, and were partly open towards the basal chamber After 48 h (iii). (B) Low voltage STEM images
of the polyester ﬁlters conﬁrming the uptake and transcytosis of MWNTs-NH3þ across the PBEC monolayer. MWNTs-NH3þ appeared within endocytic vesicles after (i) 4 and (ii) 24 h.
The MWNTs-NH3þ-containing vesicles were then imaged partly open towards the basal chamber allowing the release of MWNTs-NH3þ after 48 h (iii). The three detection modes:
bright ﬁeld (BF), annular dark ﬁeld (ADF) and high angular annular dark ﬁeld (HAADF) helped identifying the electron dense structures of MWNTs-NH3þwithin the cell body, and the
osmium-rich lipid membranes surrounding the nanostructures. Scale bars: (A) 1 mm and (inset) 500 nm. (B) First and second row 500 nm and last row 400 nm.
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regulated by the endothelial cell, and is not a damaging effect of
the MWNTs-NH3þ.
Besides MWNTs-NH3þ, we examined the ability of MWNTs-
COOH to cross PBEC cells in vitro, to determine whether the up-
take is charge-dependent. Interestingly, all f-MWNT studied trig-
gered vesicular uptake regardless of charge, indicating that in vitro
BBB transcytosis was charge-independent (Fig. S6).
The stability of MWNTs-NH3þ following uptake into PBEC was
studied using high resolution TEM (HRTEM) and Electron Energy
Loss Spectroscopy (EELS). Fig. S7 showed no evidence of breaking
down within the cells indicated by the preserved graphitic struc-
ture of the MWNTs-NH3þwithin the vesicles. Further details on this
part of results are provided in the SI Text.
3.4. The interaction of individual MWNTs-NH3
þ with the PBEC
monolayer
One of the advantages of using MWNTs-NH3þ as nanocarriers is
their ability to cross biological membranes. The needle shape, yet
ﬂexible structure allows MWNTs-NH3þ to cross plasma membranes
without utilizing the cellular endocytic processes. Many studies
have established the ability of MWNTs-NH3þ to cross biological
membranes by direct translocation in addition to active uptake
mechanisms, but none of these studies have explored bloodebrain
barrier endothelial cells. Low voltage STEM imaging in the present
study revealed that a small number of MWNTs-NH3þ were able to
pierce the plasma membrane of endothelial cells within the PBEC
monolayer. Fig. 3Ai, ii demonstrates this uptake pattern where
MWNTs-NH3þ were shown to interact with the plasma membrane
as individual carbon nanotubes, and appeared to be crossing this
membrane without any sign of membrane invagination.
MWNTs-NH3þ have also been observed exiting the EVs within
the PBEC monolayer. The MWNTs-NH3þ were able to pierce the
membrane of the EVs to access the cytosol (Fig. 3Aiii, iv). It is
possible thatMWNTs-NH3þwere routed from the EVs. However, one
cannot exclude the possibility that theMWNTs-NH3þmay have been
entering the vesicle instead.
Fig. 3 shows that some individual MWNTs-NH3þ were able to
move freely within the brain endothelial cells by crossing the
cellular membranes. This ability provides a unique internalization
route for MWNTs-NH3þ to evade the conventional transcytosis
mechanisms used by other nanocarriers, which could be advanta-
geous from a drug delivery point of view. A complete translocation
of the plasma membrane by individual MWNTs was observed in
only one instance (Fig. 3B). However, this single MWNTs-NH3þ was
surrounded by a thin membrane, which may indicate that the
MWNTs-NH3þ was taken into the endothelial cell by the active
endocytic mechanism. Very few individual MWNTs-NH3þ were
observed crossing the plasma membrane in our uptake studies
compared to the large numbers of MWNTs-NH3þ entering the
endothelial cells in vesicles. Therefore, the data presented thus far
is insufﬁcient to draw a conclusion regarding the uptake of indi-
vidual MWNTs-NH3þ, and more experiments are needed to under-
stand this route of uptake, which has been described extensively for
other cell types [22e24].
3.5. Uptake inhibition of MWNTs-NH3
þ in PBEC
At 37 C, the entry of MWNTs-NH3þ into the PBEC monolayer
occurred mostly via vesicular uptake with MWNTs-NH3þ clusters
being transported from the apical to the basal side of the endo-
thelial cell. To examine the effect of temperature on the trans-
cytosis, MWNTs-NH3þ were incubated with the cells for 4 h at 4 C
to inhibit the energy-dependent route of uptake. Low voltage
STEM imaging conﬁrmed that incubating the cells with the
MWNTs-NH3þ at 4 C resulted in inhibition of vesicular uptake.
Fig. 4, AieAiv (black and white arrow heads) showed the accu-
mulation of MWNTs-NH3þ at the apical side of the endothelial cells.
As vesicle formation was inhibited at the low temperature, the
MWNTs-NH3þ clusters were unable to enter the PBEC monolayer.
This observation provides further evidence that MWNTs-NH3þ
uptake is dependent on cellular endocytosis mechanisms. How-
ever, the MWNTs-NH3þ clusters that were unable to enter the cell
were observed at sites adjacent to endothelial tight junctions
showing some interaction with cellular extensions. To examine
this phenomenon further, we measured the distance between the
centre of the MWNTs cluster and the point of apical access to the
tight junction (shown by asterisks). The distance was estimated to
be (620.2 ± 152.5 nm, n ¼ 4). Further studies need to be carried out
to conﬁrm theMWNTs-NH3þ speciﬁcity for the para-junctional zone.
A few individual MWNTs-NH3þ were able to pierce the plasma
membrane during the 4 C incubation. Fig. 4B shows an example of
an individual MWNTs-NH3þ that was able to penetrate the plasma
membrane. The piercingmechanism can therefore be considered as
an energy-independent mechanism allowing MWNTs-NH3þ to
permeate through lipid membranes independent of active uptake
mechanisms. However, it appears to contribute only a small frac-
tion of MWNTs-NH3þ cell entry. This suggested that some individual
MWNTs-NH3þ can enter the cell in a passive energy-independent
pathway.
3.6. MWNTs-NH3
þ localization within astrocytes after crossing the
BBB
The presence of MWNTs-NH3þ in the basal chamber, both in the
medium and within the astrocytes, was investigated to further
conﬁrm the crossing of the PBEC monolayer. Fig. 5A shows the
MWNTs-NH3þ that were found in the medium following the
crossing of the PBEC monolayer and the open pores. Fig. 5B shows
that following the crossing of the PBEC monolayer, MWNTs-NH3þ
appeared to interact with the astrocyte layer and accumulated
within the cell body. Individual MWNTs-NH3þwere observedwithin
the astrocytes after 24 h, which further proves the ability of
MWNTs-NH3þ to cross BBB in vitro. HAADF images were obtained to
map the electron density of the observed structures and therefore
conﬁrm their nature. HAADF images (Fig. S8) show the structure of
MWNTs in high contrast against the cell background indicating the
high electron density, which is characteristic of the MWNTs-NH3þ.
HAADF images and their BF counterparts provided a direct conﬁr-
mation of the nature of the nanomaterial in the astrocytes.
MWNTs-NH3þwere observed in the cytoplasm of astrocytes with
no clear associationwith sub-cellular organelles. This indicates that
MWNTs-NH3þ crossed the plasma membrane of astrocytes without
any membrane invagination, which was different from that
observed in PBEC. The ability of MWNTs-NH3þ to utilize multiple
uptake routes into the cells, i.e., vesicular route of MWNTs-NH3þ
clusters into PBEC and direct membrane crossing of individual
MWNTs-NH3þ into astrocytes, shows the potential for using
f-MWNTs to target multiple cell types in vivo. It is worth noting that
the median length and diameter of the f-MWNTs (~233.9 nm and
~21.9 nm, respectively) (Fig. 5C) were comparable to that of the
starting material (Fig. S2B). Overall, the presence of MWNTs-NH3þ
within the astrocytes conﬁrmed the ability of MWNTs-NH3þ to cross
the BBB in vitro.
3.7. Transport of radiolabelled MWNTs-DTPA across the PBEC
monolayer in an in vitro BBB model
DTPA-MWNTs constructs were labelled with 111Indium as
detailed in the methods. Following the labelling reaction, the
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Fig. 3. Translocation of “individual” MWNTs-NH3þ across the PBEC membrane. Individual MWNTs-NH3þ shows an apparent ability to pierce through the plasma membrane. (A)
Bright ﬁeld STEM images showing a single MWNTs-NH3þ (black and white arrow heads) crossing the plasma membrane of endothelial cells (i, ii). The ADF and HAADF images clearly
demonstrate part of the nanotube on the other side of the plasma membrane. The ability of MWNTs-NH3þ to permeate through plasma membranes was not only demonstrated at
the plasma membrane level, but also seen as a transport method within the cell (iii, iv). (B) Electron micrographs showing a single nanotube that does not appear to be associated
with other sub-cellular compartments. Close examination reveals the presence of a thin membrane around the single nanotube. Scale bars (A) from top to bottom, 400 nm, 300 nm
and 100 nm, 300 nm. (B) 500 nm.
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Fig. 4. Inhibition of MWNTs-NH3þ uptake into endothelial cells following the incubation of MWNTs-NH3þ at 4 C. (A) The transport experiment was carried out at 4 C for 4 h to
evaluate the energy dependency of MWNTs-NH3þ uptake into the endothelial cells. Low voltage STEM images show the accumulation of MWNTs-NH3þ outside the endothelial cells
after 4 h of incubation, but no evidence of vesicular uptake was observed. The images conﬁrmed that transcytosis of MWNTs-NH3þ was governed by an active mechanism. The
MWNTs-NH3þ were mostly observed around endothelial extensions (arrow heads) in the vicinity of a tight-junctional zone (asterisks) (ieiii). (B) Electron micrographs showing a
single MWNTs-NH3þ interacting with the endothelial extension at 4 C (i, ii). Part of the MWNTs-NH3þ appeared on the other side of the plasma membrane. Scale bars (A) from top to
bottom, 500 nm, 400 nm and 500 nm, 1 mm. (B) From top to bottom 500 nm and 300 nm.
radiolabelling efﬁciency was measured by TLC. Fig. S9A shows
labelling efﬁciency of [111In]DTPA-MWNTs to be 8.1%. The labelled
constructs were tested for [111In]DTPA contamination by running
the TLC using 3.5% NH4þ:methanol (1:1) as the mobile phase.
Fig. S9B conﬁrms the presence of only negligible amount of free
DTPA (4.4%) in the sample.
The amount of [111In]DTPA-MWNTs that crossed the PBEC
monolayer into the basal chamber of the Transwell™ system over
72 h incubation period was assessed using 111In as radioactive
tracer (Fig. 6A). The radioactivity detected in the basal chamber was
directly related to the amount of [111In]DTPA-MWNTs which
crossed the PBEC monolayer. The percentage transport of [111In]
DTPA-MWNTs was measured at 37 C and 4 C. [111In]DTPA-
MWNTs percentage transport at 37 C was 5.02 ± 0.4% at 4 h.
However, the percentage transported increased considerably after
24 h to 9.1 ± 0.9%, and reached a maximum of 13.0 ± 1.1% at 72 h.
Incubating the cells at 4 C for the initial 4 h resulted in a slight but
signiﬁcantly lower % transport (2.4 ± 0.6%) than that obtained at
37 C (p ¼ 0.0005, One way ANOVA test). This difference was
abolished by 72 h upon the re-incubation of Transwells™ at 37 C
(12.0 ± 1.5%).
The stability of the [111In]DTPA-MWNTs prior to and during the
time course of the study was conﬁrmed using TLC. Fig. 6B shows
that [111In]DTPA-MWNTs were stable (>80%) after 24 h incubation
in PBS or 50% serum at 37 C making the system suitable to carry
out the transport studies. Fig. 6C shows that the measured signals
that remained in the apical chamber and the ones transported
across PBEC monolayer (sampled from the basal chamber) corre-
sponded to [111In]DTPA-MWNTs and not [111In]EDTA. This was
concluded from the ﬁnding that >80% of the signals on the TLC strip
remained at the application point (data not shown). This conﬁrms
that the radioactivity measured correspond to the transport of
labelled [111In]DTPA-MWNTs and not [111In]EDTA.
To ensure the integrity of the PBEC throughout the transport
study and to correct for variations between experiments, [111In]
EDTA was used as a marker. Fig. 6A shows the transport proﬁle of
[111In]EDTA with a sharp increase in the transported [111In]EDTA
over the early time points until it plateaued reaching amaximum of
45.3 ± 1.3% at 72 h. The % transport of [111In]EDTAwas signiﬁcantly
higher than that of the [111In]DTPA-MWNTs at all the time points
(p < 0.0001), further evidence that signals were related to [111In]
DTPA-MWNTs transport, and not [111In]EDTA. Another perme-
ability marker, [14C]sucrose, was used to assess the paracellular
permeability in the PBEC BBB model, and to study the potential
effect of [111In]DTPA-MWNTs on the tight junction stability. Fig. S10
shows that the % permeation of [14C]sucrose increased over time
and reached a maximum of 35.4 ± 1.5% at 72 h incubation at 37 C.
Incubating the cells with [14C]sucrose in the presence of [111In]
DTPA-MWNTs showed no signiﬁcant effect on the overall perme-
ation of [14C]sucrose into the basal chamber. This was an indirect
evidence that [111In]DTPA-MWNTs did not damage the cells or the
tight junction assemblies, which conﬁrmed the TEM imaging.
Additional experiments were conducted where Transwell™
ﬁlters (without PBEC) were used to measure the transport of [111In]
DTPA-MWNTs, [111In]EDTA and [14C]sucrose across the ﬁlter. [111In]
DTPA-MWNTs showed higher transport than obtained with PBEC
monolayer, and the transport proﬁle was different showing a sharp
increase in the measured signal at the early time points in the
Fig. 5. Uptake of MWNTs-NH3þ into primary astrocytes following PBEC transcytosis. Electron micrographs showing the fate of MWNTs-NH3þ following the crossing of the PBEC
monolayer. MWNTs-NH3þ were tracked into the basal chamber after 24 h of incubation with PBEC. (A) The structure of MWNTs-NH3þ in the medium of the basal chamber following
crossing the PBEC/ﬁlter. (B) Electron micrographs showing the uptake of MWNTs-NH3þ into the primary astrocytes. Individual MWNTs-NH3þ were observed within the astrocytes
with no evidence of vesicular uptake. (C) Length and diameter distribution histogram (n ¼ 100) of the studied MWNTs-NH3þ. The median length and diameter of the MWNTs-NH3þ
was 233.9 nm and 21.9 nm, respectively. Scale bars ¼ 500 nm.
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absence of the PBEC monolayer (Fig. S11). In addition [111In]DTPA-
MWNTs did not alter the permeation of [14C]sucrose across the
ﬁlter (Fig. S12).
The above studies were all carried out in a serum-free medium
to maintain the tight junction assemblies between adjacent endo-
thelial cells. The effect of serum on the [111In]DTPA-MWNTs
transport across PBECwas assessed in another study comparing the
transcytosis rate in the presence or absence of serum. Fig. S13
shows that the transport proﬁle of [111In]DTPA-MWNTs across the
PBEC monolayer was similar in the presence or absence of serum,
but with a slight but signiﬁcant reduction in transport in the
presence of serum.
TEER values were monitored during the time course of the
experiment to determine the effect of MWNTs-NH3þ incubation on
the tight junctions between adjacent PBEC. Fig. S14 shows that the
incubation of MWNTs-NH3þ caused TEER to drop from 501.3 ± 183.2
to 219.1 ± 49.2 U cm2. However, TEER remained above the
acceptable >200 U cm2 threshold throughout the experiment.
The apparent permeability coefﬁcient (Papp) was calculated for
the tested compounds (Table 1). The Papp of [111In]DTPA-MWNTs
was signiﬁcantly lower than that of [14C]sucrose, which indicated
that [111In]DTPA-MWNTs cross the BBB at a lower rate than sucrose
possibly through a different route. As expected, the Papp of [111In]
DTPA-MWNTs at 37 C was higher than that at 4 C. In addition, the
Papp of sucrose was not affected by presence or absence of [111In]
DTPA-MWNTs.
3.8. Bio-distribution of [111In]DTPA-MWNTs in mice following i.v.
administration
The ability of [111In]DTPA-MWNTs to accumulate in mouse brain
after systemic administration was studied using gamma counting.
[111In]DTPA-MWNTs was injected in C57/B16 mice via i.v. admin-
istration and the biodistribution in themajor organswasmonitored
at speciﬁc time points. To eliminate interference from blood, ani-
mals were perfused with heparinized saline before collecting the
Fig. 6. The percentage of [111In]DTPA-MWNTs transported across the PBEC monolayer over 72 h. [111In]DTPA-MWNTs (20 mg/ml) were added to the apical chamber and
incubated with PBEC at 37 C or 4 C (for the initial 4 h) followed by 37 C incubation up to 72 h. The radioactivity in the basal chamber was measured in 0.5 ml aliquots at different
time points (A). [111In]EDTA was used as a control. [111In]DTPA-MWNTs incubated at 37 C crossed the PBEC monolayer and were detected in the basal chamber reaching a
maximum of 13.0 ± 1.1% after 72 h. The incubation at 4 C signiﬁcantly decreased the uptake of [111In]DTPA-MWNTs at 2 h (p < 0.05) and 4 h (p < 0.001) which then increased to the
same level as those at 37 C, reaching a maximum of 12.0 ± 1.5%. The uptake of [111In]EDTA showed signiﬁcantly higher permeation at all time points studied compared to [111In]
DTPA-MWNTs, reaching a maximum of 45.3 ± 1.3% after 72 h (p < 0.0001). Inset to the right shows the difference in [111In]DTPA-MWNTs uptake during the initial 4 h of incubation.
(One way ANOVA test; *p < 0.05, ***p < 0.001, ****p < 0.0001, n ¼ 3). (B) the stability of the radioactive tag on the [111In]DTPA-MWNTs as measured by TLC using 0.1 M ammonium
acetate buffer containing 50 mM EDTA. Radio-labelled [111In]DTPA-MWNTs were incubated with PBS or 50% serum at 37 C for 24 h prior chromatographic analysis. (C) The
radiolabelling stability of [111In]DTPA-MWNTs during the time course of the transport experiments measured in the apical and basal chamber of the co-culture model, respectively.
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organs for gamma counting. Fig. 7A and Fig. S15A shows the bio-
distribution proﬁle of [111In]DTPA-MWNTs in the major organs and
the blood. [111In]DTPA-MWNTs accumulated mainly in the lungs
(26.5 ± 3.9 %ID) and liver (18.8 ± 0.7 %ID) 5 min after injection. The
level of [111In]DTPA-MWNTs remained relatively high in the lung
and liver after 24 h. The blood proﬁle showed that 14.4 ± 0.4 %ID of
[111In]DTPA-MWNTs were circulating in the blood after 5 min, this
level decreased over time to reach 1.3 ± 0.3 %ID after 24 h Fig. 7B
shows the level of [111In]DTPA-MWNTs accumulation in the brain
over time. The highest level was achieved 5 min after injection
reaching 0.4 ± 0.1 %ID (z1.1 ± 0.3 %ID/g). The detected levels of
[111In]DTPA-MWNTs gradually decreased over time to reach
0.18 ± 0.08% after 24 h.
The capillary depletion method was carried out to examine the
distribution of [111In]DTPA-MWNTs in the capillaries and brain
parenchyma. Fig. 7C shows that a signiﬁcant amount of [111In]
DTPA-MWNTs was detected in the capillary fraction (0.3 ± 0.09 %
ID) compared to the parenchyma (0.09 ± 0.01 %ID). However, the
detected signal in the capillaries decreased over time coupled with
a slight increase in the parenchyma fraction. Interestingly, [111In]
DTPA-MWNTs remained in the parenchyma even 24 h after injec-
tion (0.15 ± 0.06 %ID) while the levels in the capillaries diminished
considerably (0.03 ± 0.01 %ID). These results provide the ﬁrst
insight into the ability of f-MWNTs to reach brain parenchyma
following systemic administration.
4. Discussion
Despite the promise of amine-functionalized CNT in exerting a
therapeutic action in rodent's stroke models, none of the reported
studies [4], including ours [5], encountered the blood-brain barrier
during the delivery process. CNTs were directly delivered to brain
tissues by intra-ventricular [4] or intracranial injection [5]. Only
one study administered SWNTs via gastro-gavage to deliver
acetylcholine (ACh) to the brain of an Alzheimer disease mice
model (AD mice). Improvement in learning and memory capabil-
ities were obtained compared to SWNTs alone or to the free ACh.
This study provided indirect evidence that SWNTs were able to
reach the brain despite the presence of the BBB [25]. However, no
direct evidence on brain uptake was provided.
The main focus of the present paper is to examine the ability of
MWNTs-NH3þ to cross PBEC cells in vitro and to reach brain pa-
renchyma after systemic injection in mice. MWNTs-NH3þwere used
in this study for the following reasons: (i) they proved their efﬁcacy
as siRNA carriers to neural cells after local injection in the brain [5]
(ii) they elicited no inﬂammatory response compared to the oxi-
dised equivalent, ox-MWNTs-NH3þ, which caused a reversible
transient immune response [26]; (iii) biodegradation of MWNTs-
NH3þ in brain cells, following stereotactic injection in the brain
cortex of mice, has been shown microscopically [27]. Moreover, we
hypothesize that the slightly cationic nature of the MWNTs-NH3þ
could improve their cellular uptake into endothelial cells via
adsorptive-mediated endocytosis routes [28].
The main obstacle in studying the mechanism of nanoparticle
uptake across the BBB is ﬁnding a representative in vitro BBB model
which closely mimics the characteristics of the in vivo BBB. Several
models have been described using immortalized endothelial cell
lines such as mouse brain endothelial cells bEnd.3 [29], rat brain
endothelial cells RBE4 [30,31], and hCMEC/D3 human endothelial
cells [32]. Primary cultures of brain endothelial cells provide a better
polarized BBB model compared to immortalized cell lines. Some
examples include primary bovine brain microvessels endothelial
cells (BMEC) [33] and porcine brain endothelial cells [34]. Evidence
from a variety of studies conﬁrms that co-culture of primary endo-
thelial culture with primary astrocytes gives more complete BBB-
like features by increasing the BBB phenotype and reducing non-
brain endothelial speciﬁc features. The quality of the BBB model is
generally assessed by TEER measurement, and permeability index
[11].
The PBEC/astrocyte BBBmodel used in this experiment is awell-
established model that has been previously reported and charac-
terized. Rubin et al. described the isolation of bovine brain endo-
thelial cells and the successful establishment of an in vitro co-
culture model of endothelial cells and primary astrocytes [10].
Based on thismodel, PBEC have been isolatedwithmodiﬁcations by
Skinner et al. and were used to set up a BBB model of PBEC and
primary astrocytes identical to that used in our work [19]. TEERwas
used to characterize the tightness of the PBEC monolayer, which
reﬂected the state of tight junctions between the cells. Even though
no cell surface markers were used to characterise PBEC, the high
TEER values were characteristic of brain capillary endothelial cells.
This is conﬁrmed by the work of Butt et al. who showed the dif-
ference between TEER in brain surface (BBB) pial microvessel
(>1000 U cm2) compared to TEER reported in the peripheral
microvessels (2e20 U cm2) [35]. Therefore, in our model, we relied
on TEER measurement to assess the presence of tight junctions
indicative of healthy brain endothelial cells. TEER >200 U cm2 was
the threshold below which we rejected the model.
A key advantage of using a co-culture model is enhancing the
polarity of the PBEC monolayer and inducing the expression of
surface receptors that distinguish brain endothelial cells from pe-
ripheral endothelial cells [36]. The polarity of the endothelial cells
is vital when studying transcytosis across the BBB and for the
expression of luminal/abluminal-speciﬁc receptors and trans-
porters. Laakkonen et al. have studied the transcytosis of adeno-
virus vectors across hCMEC/D3 cells, and showed a marked
difference in the transduction between polarized hCMEC/D3 grown
on Transwell™ ﬁlters coated with rat-tail collagen type I and the
un-polarized hCMEC/D3 cells grown in cell culture plates [36].
Co-culture models have been used to study nanoparticle
transport across the BBB. The uptake of transferrin-decorated li-
posomes [37], citrate-coated gold nanospheres [38] and gold
nanoparticles [39] was investigated in the hCMEC/D3 in vitro BBB
model [37e39]. Superparamagnetic iron oxide and polymeric
nanoparticle uptake across the BBB was studied in a co-culture
model of human brain capillary endothelial cells obtained from a
female epilepsy-sufferer and immortalized by transfection with
simian virus 40 T antigen [40,41]. Silver nanoparticles were applied
in a co-culture of rat brain microvessel vascular endothelial cells
BMVECs [42]. However, to our knowledge no report has been
published on the uptake characteristics of CNTs in any BBB model
in vitro or in vivo. The closest was a study by Bhattacharya et al. who
Table 1
Apparent permeability coefﬁcient (Papp) of [111In]DTPA-MWNTs and [14C]sucrose across PBEC.
[111In] MWNTs (37 C) [111In] MWNTs (4 C) [111In]EDTA (37 C) [14C]sucrose (37 C)a [14C]sucrose (37 C)b
Papp (cm/s)  106 0.2 ± 0.02 0.05 ± 0.02 1.03 ± 0.06 8.6 ± 2.1 8.9 ± 0.8
Values are presented as mean ± SD, n ¼ 3.
a In the absence of [111In] MWNTs.
b In the presence of [111In] MWNTs.
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examined the uptake of SWNTs-DNA hybrids into human umbilical
vein endothelial cells (HUVECs). The SWNTs-DNA constructs were
able to enter the cells and to accumulate within vesicles after 6 h of
incubation [43]. The mechanistic studies carried out using speciﬁc
endocytosis inhibitors pinpointed macropinocytosis as the main
route of uptake as opposed to clathrin- or caveolae-dependant
endocytosis. In the present study, the behaviour of MWNTs-NH3þ
in PBEC was similar to that of SWNTs-DNA in HUVECs. MWNTs-
NH3þ were able to enter and accumulate within endocytic vesicles
within 24 h followed by complete transcytosis for some of the
vesicles. Incubating the cells at 4 C signiﬁcantly reduced the up-
take and transcytosis as shown by the [111In]DTPA-MWNTs trans-
port study. This was supported by the STEM images showing the
MWNTs-NH3þ interacting with PBECs, but not within the cell at 4 C.
These observations conﬁrmed the involvement of an energy-
dependant process in the transcytosis of MWNTs-NH3þ across the
PBEC layer. Morphological observations by STEM suggested that
macropinocytosis is the main route of uptakemainly due to the size
of the MWNTs-NH3þ and the observation of lipid rufﬂes engulﬁng
the MWNTs-NH3þ, which is characteristic of macropinocytosis [44].
However, more studies are needed to conﬁrm the speciﬁc endocytic
route(s) involved in MWNTs-NH3þ uptake across PBEC.
Studying the uptake of CNTs into endothelial cells has been
previously reported using light microscopy [45] and conventional
TEM [46]. The use of low voltage STEM imaging to study the uptake
and transcytosis of MWNTs-NH3þ in PBEC provided several advan-
tages as we show for the ﬁrst time the transport of MWNTs-NH3þ
over 48 h in three distinct detectionmodes. The ability to image the
cells using BF, ADF and HAADF in parallel provided an invaluable
tool to analyze the interaction between MWNTs-NH3þ and the
osmium-stained cellular membranes e.g. plasma membranes and
endocytic membranes. Previous studies have explored high-end
imaging tools to study the interaction of CNTs with immortalized
cells and primary cultures [7,47], but none has used a fully polarized
cell type as in this BBB model, which is important in reproducing
the vectorial movement of nanoparticles.
Only two earlier studies report the use of PBEC to study the
uptake of nanoparticles. PBEC were used to study the uptake
characteristics of third-generation (G3) PAMAM nanoparticles
conjugated to paclitaxel. The data showed that conjugating the
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Fig. 7. Organ biodistribution and brain uptake of [111In]DTPA-MWNTs into mice following i.v. administration. C57/Bl6 mice were injected with [111In]DTPA-MWNTs (50 mg,
0.5 MBq) via the tail vein. At each time point (5 min, 30 min, 1 h, 4 h and 24 h) whole body perfusion with heparinized saline was performed and major organs were harvested for
quantitative measurements of radioactivity by g-scintigraphy. (A) The accumulation of [111In]DTPA-MWNTs in the major organs after each time point. (B) Brain uptake of [111In]
DTPA-MWNTs over time showing the highest brain accumulation after 5 min. (C) The capillary depletion proﬁle showing the sustained accumulation of [111In]DTPA-MWNTs in brain
parenchyma over time compared to a gradual reduction in capillary fraction. The data is presented as % injected dose per organ. Results are expressed as mean ± SD, n ¼ 3
(***p < 0.001).
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drugmolecule to PAMAM resulted in signiﬁcantly higher transport
rate across the PBEC monolayer compared to the drug alone [48].
Freese et al. have investigated the transcellular transport of gold
nanoparticles across a PBEC/astrocytes co-culture model using
TEM. The results showed that gold nanoparticles were able to
enter the cells and accumulate in vesicles within 24 h. When the
experiment was carried out with hCMEC/D3 cells the vesicles
containing the gold nanoparticles were observed in the peri-
nuclear region. However, the fate of the gold nanoparticles
entering the endothelial cells was not discussed in either model
[39]. In our experiments, the MWNTs-NH3þ accumulated in multi-
vesicular bodies within 24 h, but MWNTs-NH3þ-containing vesicles
were observed in the para-junctional zones rather than the peri-
nuclear region. The data presented here showed the complete
crossing of MWNTs-NH3þ in the PBEC layer after 72 h. Therefore,
we were able to demonstrate, for the ﬁrst time, the ability of
MWNTs-NH3þ to cross the BBB in vitro with low voltage STEM
imaging, thus providing solid evidence using electron microscopy
for each step of the transcytosis process. Crossing the PBEC
monolayer by transcytosis was also conﬁrmed by tracking the
MWNTs-NH3þ into the primary rat astrocytes. TEM images of the
astrocytes revealed the presence of MWNTs-NH3þ that successfully
crossed the PBEC monolayer. This observation consolidated the
conclusion regarding the crossing of the BBB in vitro by MWNTs-
NH3þ. However, the route of uptake into the astrocytes was
different from that in PBEC. MWNTs-NH3þ appeared as individual
particles as opposed to the clusters within PBEC. This pattern of
nanoparticle uptake into astrocytes was previously reported in a
study that tracked the uptake of glucose-coated gold nano-
particles across a 3D co-culture of hCMEC/D3 and primary human
astrocytes. Similar to our ﬁndings, the gold nanoparticles were
found within the astrocytes after 8 h of incubation with the
endothelial cells with no evidence of vesicular uptake [49].
“Endosomal escape” was observed in a few images. However,
lone MWNTs-NH3þ were not detected within the PBEC cytosol, as
ADF and HAADF images always identiﬁed a very thin membrane
surrounding the individual MWNTs-NH3þ within the cytoplasm.
Moreover, MWNTs-NH3þwere not observed in either the nucleus or
the mitochondria at any time point; this is in contrast to the re-
ported accumulation of CNTs in the nucleus and mitochondria of
certain cell preparations, for example the lung epithelial cell line
A549 [46,50]. The uptake experiments using [111In]DTPA-MWNTs
showed that despite incubation at 4 C, a small percentage of [111In]
DTPA-MWNTs were transported into the basal chamber. Moreover,
[111In]DTPA-MWNTs transport across PBEC showed lower Papp than
[14C]sucrose indicating that [111In]DTPA-MWNTs crossed the BBB at
a lower rate which is expected for the transcellular uptake route.
The slow transport rate observed during the initial 4 h of incubation
(by radiolabelling) agreed well with TEM/STEM images, which
showed crossing of the MWNTs-NH3þ only after 24 h. The fact that
Papp of [111In]DTPA-MWNTs at 37 C was higher than that at 4 C,
further conﬁrmed the involvement of energy-dependant uptake of
[111In]DTPA-MWNTs across the BBB.
The mechanistic in vitro studies showed extensive evidence of
the inherent ability of MWNTs-NH3þ to cross the BBB. The organ
biodistribution proﬁle suggested brain accumulation of [111In]
DTPA-MWNTs into mouse brain following intravenous adminis-
tration. However, the majority of [111In]DTPA-MWNTs was found in
the liver and lungs. This was not surprising as the same observation
was made in our previous study [51]. The highest whole brain
accumulationwas obtained at 5min post-injection (1.1± 0.3 %ID/g).
This value may seem modest compared to other organs, but it is
within the range of values reported for other types of nanoparticles,
which have shown success in brain delivery [52,53]. It is empha-
sized that whole body saline perfusion was carried out before
harvesting organs so that interference with radioactivity in circu-
lating blood is eliminated.
Previously liposomes have been used to deliver the BBB
impermeable drug serotonin tomice brain using i.v. administration.
The radiolabelled non-PEGylated liposomal serotonin achieved
higher brain accumulation compared to free serotonin after 1 and
24 h. The same study reported whole brain uptake of 0.138 ± 0.034
and 0.097% ± 0.011 %ID/g of brain after 1 and 24 h, respectively [52].
Interestingly, the non-PEGylated [111In]DTPA-MWNTs reported in
this study achieved 8-fold higher whole brain uptake than the li-
posomes reported by Afergan et al. [52]. Another study using
radiolabelled passively targeted PEGylated liposomes reported
whole brain uptake of 0.69 ± 0.06% %ID/g of after 1 h of adminis-
tration. This value is also signiﬁcantly lower than values we report
here.
In addition to signiﬁcant brain uptake reported for [111In]DTPA-
MWNTs, the brain uptake is much faster than that reported for
other nanocarriers. Notably, the highest value (Cmax) of [111In]DTPA-
MWNTs in brain was achieved at 5 min post-injection. Cmax of li-
posomes, for example, was obtained at a later time points 1 h post-
injection [52,53]. Capillary depletion results indicate rapid inter-
action with brain endothelium (~5 min), which may have contrib-
uted to the highest whole brain uptake value, at the early time
point. No time points earlier than 5 min were examined in this
study. Interestingly, the concentration in brain parenchyma was
found to be sustained over the 24 h period, which suggest either a
continuing entry into the brain parenchyma or the limited clear-
ance over the studied period.
NPs have also been studied for brain targeting using surface li-
gands. Lockman et al., studied the brain accumulation of solid NPs
made from oil-in-water microemulsions after coating with thia-
mine to target the thiamine receptors on the brain endothelium.
The data showed that 0.5 %ID (z1.1 %ID per gram of tissue) of the
injected NPs-thiamine accumulated in the brain 2 h after injection
[54]. Another study used lactoferrin-conjugated liposomes to
investigate brain targeting in mice following i.v. administration.
Lactoferrin-conjugated liposomes reached 1.02 ± 0.06 and
0.81 ± 0.05 %ID/g in mouse brain after 2 and 6 h, respectively [53].
Coincidentally, both studies reported similar values to our bio-
distribution study even though the [111In]DTPA-MWNTs were not
actively targeted to the BBB. This highlights the importance of the
datawe present herewhich is likely to improvewhen BBB targeting
ligand is conjugated to f-MWNTs.
5. Conclusions
This was the ﬁrst evidence for the unique ability of f-MWNTs to
cross the in vitro co-culture BBB model and to accumulate in mouse
brain following systemic administration in vivo. The choice of the co-
culture BBB model was based on the superiority of co-cultured
primary endothelial cell cultures in forming tight junctions,
expressing surface receptors, and demonstrating transcytosis, thus
mimicking the in vivo BBB characteristics more closely than in
immortalized endothelial cell lines. Ultra-structural imaging by TEM
and STEM was employed to gain unequivocal evidence for trans-
location of the intactMWNT-NH3þ, which also conﬁrmed the route(s)
of uptake. Electron micrographs conﬁrmed transcytosis of MWNT-
NH3þ and its sequence as a function of time. MWNT-NH3þwere found
within endocytic vesicles and multi-vesicular bodies within 4e24 h
of incubation, followed by a basal exit from PBEC cells after 48 h. ADF
and HAADF images showed clearly the lipid membranes surround-
ing the vesicles and the presence of intact plasma membranes
followingMWNT-NH3þ exit, which in combinationwith themodiﬁed
LDH assay indicated the biocompatibility of MWNT-NH3þ vectors.
Most importantly, the presence of f-MWNT in the astrocyte layer
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was also conﬁrmed by TEM. The extent of f-MWNTs transport across
the PBEC monolayer was investigated by tracking the radiolabelled
[111In]DTPA-MWNTs from apical to basal chamber. This is the ﬁrst
evidence of f-MWNT translocation across the BBB in an in vitro
model. The signiﬁcant reduction in the transport of f-MWNT across
the BBB at 4 C conﬁrmed that the uptake was driven by an energy-
dependent pathway. In vivo bio-distribution studies showed that a
substantial amount of f-MWNTs accumulated at early time points in
mouse brain following systemic administration. Capillary depletion
provided initial evidence on the presence of f-MWNTs within brain
parenchyma. Future work will focus on surface modiﬁcation of f-
MWNTs, of different diameters, with BBB targeting ligands to
examine whether brain uptake can be further enhanced.
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